From discovery to delivery

Let’s connect during the 64th ASH annual meeting and exposition, where you’ll learn how Cytiva can help you navigate the scientific, business, and regulatory challenges of making successful medicines.

Still need to register for the conference?

What’s on:

From science fiction to standard of care: Developing the next wave of genomic medicines for hematology

Monday, December 12 | 12:15-1:15 p.m. | Theater 6, Exhibit Hall J

Join Sadik Kassim, PhD Chief Technology Officer Genomic Medicines, Danaher

as he shares Cytiva’s rich history of collaboration and support of the academic pioneers
who’ve developed the tools and technologies for bringing bespoke therapies

to patients like Emily Whitehead.

*Not an official event of the 64th ASH Annual Meeting and Exposition. This presentation is not sponsored or endorsed by ASH. Not CME-accredited.

Stop by booth #2259

Say hello, connect with colleagues, and see the Sepax™ C-Pro, Cytiva’s functionally closed, automated system for cell processing, up close and in person.

Access our digital content library

Fill out the form for a link to access our collection of posters, videos, infographics, and more – curated for the interests of those on the journey of bringing novel therapies to patients.

You’ll find content on

Considerations for allogeneic therapies
Cell, gene, and mRNA therapy workflows
Creating custom media
Regulatory resources

Send me a link to the digital asset library

First Name:

Last Name:

Email Address:

Company Name:

Phone Number:

Address:

City:

Country:

State/Province Name:

Postal Code:

Tell us about your interests, so we can direct you to the most relevant resources:

I would like to be contacted by a Cytiva representative

Please explain your request:

By clicking any of these options, you are agreeing to receive marketing emails, newsletters and other promotional communications from Cytiva from time to time. You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our Privacy policy.

Privacy | Terms | Trademarks | Legal | Contact